Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

2765 - Efficacy and tolerability of transdermal fentanyl versus oral prolonged-release oxycodone/naloxone in patients with moderate to severe cancer pain: A propensity analysis comparison


09 Oct 2016


Poster display


Anna Roberto


Annals of Oncology (2016) 27 (6): 455-461. 10.1093/annonc/mdw384


A. Roberto1, M.T. Greco2, L. Legramandi3, F. Galli1, O. Corli1

Author affiliations

  • 1 Oncology, IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, 20156 - Milano/IT
  • 2 Dipartimento Di Scienze Cliniche E Di Comunità, Università degli Studi di Milano, Milano/IT
  • 3 Oncology, IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milano/IT


Abstract 2765


In cancer patients treated with opioids, both transdermal Fentanyl (TF) and oral PR Oxycodone-Naloxone (OXN) have been found effective in reducing pain, with less constipation in comparison with other opioids. No direct comparison is available between TF and OXN.


Consecutive cancer patients with moderate to severe cancer pain and naïve to WHO-III strong opioids enrolled in a two prospective 28-day studies (NCT01809106, NCT02293785) and receiving TF or OXN were selected; to adjust for bias inherent to heterogeneity and decision about their opioid therapy, we performed a propensity score analysis by multivariable logistic regression. Outcome measures included analgesic efficacy over time [worst and average pain NRS intensity decrease (APID); analgesic response (APID >30%); daily opioid dosage (morphine-equivalent MEQ, mg); daily opioid dose increase and rate of abnormal (>5%) escalation index] and safety profile as premature switch to other analgesics, constipation and other adverse events (AEs).


124 TF and 173 OXN patients were included in the comparative analysis (age 68.3 ± 10.3; female 41.8%; average pain intensity at baseline 6.2 ± 1.3). The 28-day APID were similar after TF and OXN (worst -45.3 vs -43.3%; average -53.9 vs -52.0%; both NS); response rates were also comparable (75.9% TF vs 82.5% OXN, NS), indicating similar analgesic efficacy. However, different daily MEQ dosages were used both at baseline (53.4 TF vs 25.5 mg OXN, p 


In this propensity analysis of patients with moderate-severe cancer pain, OXN showed similar analgesic efficacy compared to TF, despite strikingly lower daily dosages and need of drug escalation, suggesting less mid-term tolerance with OXN in cancer pain.

Clinical trial identification

NCT01809106, NCT0229378

Legal entity responsible for the study

IRCCS-Istituto di Ricerche Farmacologiche Mario Negri


IRCCS-Istituto di Ricerche Farmacologiche Mario Negri


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings